{
    "clinical_study": {
        "@rank": "97529", 
        "acronym": "AMOLED", 
        "arm_group": [
            {
                "arm_group_label": "Bredinin tablet 150mg", 
                "arm_group_type": "Experimental", 
                "description": "dosage form: Tablet, dosage: 150mg qd, Duration: for 6months"
            }, 
            {
                "arm_group_label": "Bredinin tablet 50mg", 
                "arm_group_type": "Active Comparator", 
                "description": "dosage form: Tablet, dosage: 50mg tid, Duration: for 6months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and\n      50mg tid in active rheumatoid arthritis patients unsuccessfully treated with\n      disease-modifying antirheumatic drug."
        }, 
        "brief_title": "Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged from 20 to 80 years old\n\n          -  Signed and dated informed consent document indicating that the patient\n\n          -  Patients must have a diagnosis of Rheumatoid Arthritis(RA) of at least 3months\n             duration as defined by the 2010 American College of Rheumatology(ACR) Classification\n             criteria.\n\n          -  Patients should have a Disease Activity Score 28 greater than or equal to 3.2 (DAS28\n             \u2265 3.2) and have received treatment with more than 1 kind of disease-modifying\n             antirheumatic drug(including MTX).\n\n          -  ESR\u226528mm/h or CRP\u22651.0mg/dl at screening.\n\n        Exclusion Criteria\n\n          -  At screening, patients have laboratory result as defined by : white blood cell \u2264\n             3,000/mm3\n\n             , Hemoglobin < 8.5 g/dL, Platelet count < 100,000/mm3, Serum creatinine > 2.0 mg/dL,\n             Aspartic Acid Transaminase/Alanine Transaminase \u2265 2*upper limit of normal , Uric acid\n              \u2265 1.5*upper limit of normal\n\n          -  Patient must not have bleeding disorder or taking anticoagulant. (But, lt is allowed\n             to take 100mg/day of Asprin)\n\n          -  Patients with a history of operation on index knee joint which could have influence\n             on the result and need to have surgery as determined by investigator.\n\n          -  Patients have severe infection, including moderate respiratory disease and have\n             received treatment with systemic antibiotics within 2 weeks.\n\n          -  Patients have cardiovascular disease or associated disease which is not controlled.\n\n          -  Patients have a history of malignancy within 5years. (But, basal cell or squamous\n             cell carcinoma or carcinoma in situ of the uterine cervix have been treated is\n             allowed)\n\n          -  Patients have hypersensitivity reaction on this drug.\n\n          -  Patients on any other clinical trial or experimental treatment in the past 3months.\n\n          -  Female patients who are breast feeding, pregnant or plan to become pregnant during\n             the trial or for two months following study termination.\n\n          -  Not allowable medication recorded below ; Intra-articular injections within  weeks at\n             baseline visit, Patients taking oral steroid over 10mg /day or using new treatment or\n             changing dosage within 4weeks at baseline visit, Using new nonsteroidal\n             antiinflammatory drug within 4 weeks or changing nonsteroidal antiinflammatory drug\n             dosage within 2 weeks at baseline visit.\n\n          -  Having experience of use biologic agent, immunosuppressant, cytostatic preparations\n             within 8weeks at baseline visit. (But, Rituximab is not allowed within 6months)\n\n          -  Start to treatment new disease-modifying antirheumatic drug or need to change dosage\n             of disease-modifying antirheumatic drug which is taking on the trial.\n             (Leflunomide(ARAVA\u00ae) is not allowed within 12weeks, But, Cholestyramine is allowed\n             after 48 hours later stopping. if it use three times a day, 8g, for 11days)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005757", 
            "org_study_id": "32RA13007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bredinin tablet 150mg", 
                "description": "Bredinin 150mg qd vs Bredinin 50mg tid", 
                "intervention_name": "Bredinin tablet 150mg", 
                "intervention_type": "Drug", 
                "other_name": "Mizoribine"
            }, 
            {
                "arm_group_label": "Bredinin tablet 50mg", 
                "description": "Bredinin 150mg qd vs Bredinin 50mg tid", 
                "intervention_name": "Bredinin tablet 50mg", 
                "intervention_type": "Drug", 
                "other_name": "Mizoribine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bredinin", 
                "Antirheumatic Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "rheumatoid arthritis", 
            "RA", 
            "Mizoribine", 
            "DAS28", 
            "European League Against Rheumatism"
        ], 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gangneung", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Gangneung Asan Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug", 
        "overall_official": {
            "affiliation": "Gangneng asan Medical center", 
            "last_name": "Sung Su Kim, M.D., Ph.D", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "all cause mortality", 
            "safety_issue": "No", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005757"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}